An AI-powered platform to improve patient assessment and cancer diagnosis across your patient population.
If you’re interested in exploring a partnership with us, please click here to get in touch with a member of our executive team directly.
Skin cancer is a pervasive and underdiagnosed health concern in the United States, exacerbated by the inefficiencies within the healthcare system, resulting in preventable morbidity. Physicians, who are on the frontline to appropriately treat and triage a host of conditions, have had a lack of adequate diagnostic aids to assess skin lesions. There is an unmet need for tools to improve the identification of lesions requiring referral, which may otherwise lead to delayed or missed detection of skin cancer.
Powered by FDA-Breakthrough technology, DermaSensor delivers accurate results at the fingertips of healthcare providers.
Designed with efficiency in mind, DermaSensor ensures rapid, objective test results without compromising quality. Its user-friendly interface makes it effortlessly accessible and easy to incorporate into the busy routine of medical offices. This powerful tool enhances and streamlines physicians’ management process for suspicious skin lesions and translates to tangible value for healthcare systems.
DermaSensor’s capabilities pave the way for more informed decision-making, since the device was found to have a 96% device sensitivity for correctly referring skin cancer in a study of 1,579 lesions and 224 skin cancers. Its rapid results can help minimize healthcare provider and patient time associated with referrals, creating a ripple effect of benefits for the healthcare ecosystem. Ultimately, DermaSensor improves PCPs cancer detection and appropriate referrals to dermatology, marking a significant advancement in skin cancer care in the U.S.
Empowering Clinicians with Enhanced Precision
DermaSensor is a real-time, non-invasive skin cancer evaluation system that provides point-of-care testing for all types of skin cancer.
The Burden of Skin Cancer
In the U.S., more than 9,500 people are diagnosed with skin cancer every day. More than two people die of the disease every hour and at least one in five Americans will develop skin cancer by the age of 70.*
While skin cancer is highly treatable at early stages, delays in identification substantially increased risk. Effective assessment of patients with potential skin cancer in primary care settings can be challenging due to handling diverse and increasing medical concerns and having limited dermatological training. But now, physicians can use DermaSensor’s AI-powered spectroscopy technology to non-invasively evaluate cellular and subcellular characteristics of a lesion in question for skin cancer. The wireless, handheld device then provides an immediate, objective result using the FDA-cleared algorithm.
$199/month(Up to 5 patients)
$399/month(Unlimited Users & Scans)
Discover what other practitioners are saying.